Clinical trials: Renal Cell Carcinoma Metastatic
Renal Cell Cancer
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
The purpose of this research is to test the response of study participants' tumor to pembrolizumab alone, and in combination with axitinib, and to see what effects (good and bad) these drugs have on patients with advanced kidney…
- Trial name
- NCT05263609
- Testing
- Axitinib, Pembrolizumab
- Sponsor
- University of Oklahoma
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Renal Cell Carcinoma
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial…
- Trial name
- NCT06770855
- Testing
- Total consolidative MPDT
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Clear-cell Renal Cell Carcinoma, RCC
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms.
- Conditions
- Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
- Trial name
- NCT03035630
- Testing
- Avelumab, Sunitinib
- Where
- United States
- Sponsor
- Guru Sonpavde
Kidney Cancer
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: When irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells.
- Trial name
- NCT00176501
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rutgers, The State University of New Jersey
Kidney Cancer
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00496756
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Metastatic Renal Cell Carcinoma, Kidney Cancer
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
The purpose of this study is to test the safety of bevacizumab and sunitinib given in combination for kidney cancer. The drugs act to stop blood vessel growth but in different ways.
- Trial name
- NCT00421512
- Testing
- Bevacizumab and Sunitinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Trial name
- NCT00056095
- Testing
- therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine
- Where
- 26 sites in France
- Volunteers
- 57 people
- Sponsor
- UNICANCER
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Melanoma; Renal Cell Carcinoma
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may…
- Trial name
- NCT03728842
- Testing
- Blood collection for laboratory studies, Data collection from medical record
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Metastatic Melanoma, Renal Cell Cancer
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Background: -Although IL-2 can shrink tumors in about 20 percent of patients with metastatic kidney cancer and in 15 percent of patients with metastatic melanoma, it is not fully known how the drug works.
- Trial name
- NCT00304460
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have…
- Trial name
- NCT03699579
- Where
- 2 sites in Taiwan
- Volunteers
- 28 people
- Sponsor
- Ipsen
Kidney Cancer
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00003683
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 14 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Metastatic Renal Cell Carcinoma
A Phase II Study of AS1411 in Renal Cell Carcinoma
The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma
- Trial name
- NCT00740441
- Testing
- AS1411
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Antisoma Research
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer
Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Optimizing Pazopanib Exposure in RCC Patients
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
- Trial name
- OPERA (NCT02089802)
- Testing
- Pazopanib
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.